MicroRNAs and breast cancer

doi:10.3760/cma.j.issn.1673-422X.2014.01.012

Abstract

Abstract: MicroRNAs (miRNAs) are a class of small molecule noncoding RNAs. Those RNAs are considered as oncogenes and tumor suppressor genes in breast cancer and can be a promoter or inhibitor in tumor invasion and metastasis cascade stages, and they are also closely related to the tumor epithelialmesenchymal transition and tumor stem cell generation. New researches show that miRNAs can serve as significant diagnostic and prognostic indicators to provide a theoretical basis for the biotherapy of targeting miRNAs which is applied to the clinical diagnosis and treatment of breast cancer.

Key words: MicroRNAs, Breast neoplasms, Neoplasm metastasis, Diagnosis, Molecular targeted therapy

Zhang Tingting, Liu Yongjun, Liang Ailing. MicroRNAs and breast cancer[J]. Journal of International Oncology, 2014, 41(1): 37-40.

References

［1］ Zhang B, PanX, Cobb G, et al. MicroRNAs as oncogenes and tumor suppressors［J］. Dev Biol, 2007, 302(1):112. ［2］ Manikandan J, Aarthi JJ, Kumar SD, et al. Oncomirs: the potential role of noncoding microRNAs in understanding cancer［J］. Bioinformation, 2008, 2(8):330334. ［3］ Connolly EC, Van Doorslaer K, Rogler LE, et al. Overexpression of miR21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB［J］. Mol Cancer Res, 2010, 8(5):691700. ［4］ Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines［J］. Gastroenterology, 2006, 130(7):21132129. ［5］ Zhu S, Si ML, Wu H, et al. MicroRNA21 targets the tumor suppressor gene tropomyosin 1 (TPM1)［J］. J Biol Chem, 2007, 282(19):1432814336. ［6］ Zhu, S, Wu H, Wu F, et al. MicroRNA21 targets tumor suppressor genes in invasion and metastasis［J］. Cell Res, 2008, 18(3):350359. ［7］ Shah MY, Calin GA. MicroRNAs miR221 and miR222: a new level of regulation in aggressive breast cancer［J］. Genome Med, 2011, 3(8):56. ［8］ Li J, Kong X, Zhang J, et al. Correction: miRNA26b inhibits proliferation by targeting PTGS2 in breast cancer［J］. Cancer Cell Int, 2013, 13(1):17. ［9］ Taube JH, Herschkowitz JI, Komurov K, et al. Core epithelialtomesenchymal transition interactome geneexpression signature is associated with claudinlow and metaplastic breast cancer subtypes［J］. Proc Natl Acad Sci USA, 2010, 107(35):1544915454. ［10］ Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer［J］. Oncogene, 2010, 29(34):47414751. ［11］ Liang YJ, Wang QY, Zhou CX, et al. MiR124 targets Slug to regulate epithelialmesenchymal transition and metastasis of breast cancer［J］. Carcinogenesis, 2013, 34(3):713722. ［12］ Stinson S, Lackner MR, Adai AT, et al. MiR221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelialtomesenchymal transition in breast cancer［J］. Sci Signal, 2011, 4(186):pt5. ［13］ Han M, Liu M, Wang Y, et al. Reexpression of miR21 contributes to migration and invasion by inducing epithelialmesenchymal transition consistent with cancer stem cell characteristics in MCF7 cells［J］. Mol Cell Biochem, 2012, 363(12):427436. ［14］ Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells［J］. Int J Mol Sci, 2013, 14(7):1471214723. ［15］ Liu S, Patel SH, Ginestier C, et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells［J］. PLoS Genet, 2012, 8(6):e1002751. ［16］ Qian B, Katsaros D, Lu L, et al. High miR21 expression in breast cancer associated with poor diseasefree survival in early stage disease and high TGFbeta1［J］. Breast Cancer Res Treat, 2009, 117(1):131140. ［17］ Wu ZS, Wu Q, Wang CQ, et al. MiR340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein cMet［J］. Cancer, 2011, 117(13): 28422852. ［18］陈晓兰，秦树佩，杨建新. 微小RNA与乳腺癌细胞的增殖与转移［J］. 国际肿瘤学杂志, 2012， 39(4): 265268. ［19］ Ma L, TeruyaFeldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA10b in breast cancer［J］. Nature, 2007, 449(7163): 682688. ［20］ Sun Y, Wang M, Lin G, et al. Serum microRNA155 as a potential biomarker to track disease in breast cancer［J］. PLoS One, 2012, 7(10):e47003. ［21］ Lu Z, Ye Y, Jiao D, et al. MiR155 and miR31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status［J］. Oncol Lett, 2012, 4(5):10271032. ［22］ Wang H, Tan G, Dong L, et al. Circulating miR125b as a marker predicting chemoresistance in breast cancer［J］. PLoS One, 2012, 7(4):e34210. ［23］ Liu Y, Zhao J, Zhang PY, et al. MicroRNA10b targets Ecadherin and modulates breast cancer metastasis［J］. Med Sci Monit, 2012, 18(8):BR299308. ［24］ Li J, Shen L, Xiao XG, et al. MicroRNAs in breast cancer and breast cancer stem cells and their potential for breast cancer therapy［J］. Chin Med J (Engl), 2013, 126(13):25562563. ［25］ Kota J, Chivukula RR, O′Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model［J］. Cell, 2009, 137(6):10051017. ［26］ Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells［J］. Nat Methods, 2007, 4(9):721726. ［27］ Ma L, Young J, Prabhala H, et al. MiR9, a MYC/MYCNactivated microRNA, regulates Ecadherin and cancer metastasis［J］. Nat Cell Biol, 2010, 12(3):247256.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[5]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[6]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[7]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[8]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[9]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[10]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[11]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[13]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[14]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[15]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.